N/A N=41 A Proof-of-principle Study of HBO-SRS for Brain Metastases
Brain Metastases
Primary: The Average Time From HBO Chamber Exit to SRS beam-on — 8.3 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=58 Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]
Diarrhea
Primary: Percentage of Participants With Adverse Events — 100; 100.0; 100.0; 91.7 percentage of participants
Phase 2 N=811 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
N/A N=476 Peer Empowerment Program for Physical Activity in Low Income and Minority Seniors
Physical Activity
Primary: Minutes of Physical Activity as Measured by Accelerometer — 20.0; 19.2 Minutes
Phase 3 N=93 Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
ATTR-PN
Primary: Val30Met Group: Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Baseline — 6.8; 11.6 units on a scale
N/A N=152 Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery
Venous Thrombosis
Primary: Development of DVT (Deep Vein Thrombosis)
Phase 2 N=142 A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs — 65; 66; 32; 28 Participants
N/A N=60 Care4Today v2.0 Application for Improving Adherence to HIV Medications
HIV · AIDS
Primary: Number of Participants ≥90% Adherent to Antiretroviral Medication Based on MEMS Cap Openings — 9; 5 Participants — p=0.32
Phase 3 N=846 Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
Hypertension
Primary: dBP Change After 8 Weeks Phase A — -15.8; -18.9 mmHG — p=<0.0001
Phase 3 N=528 Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye to Week 12 (Hours 0 and 2) — -6.47; -6.18; -6.11; -7.16 millimeters of mercury (mmHg) — p=0.3738
N/A N=233 Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries
Peripheral Arterial Disease
Primary: Efficacy - Number of Participants With Freedom From MALE at 6 Months and POD at 30 Days — 200 Participants
N/A N=128 Rivanna Ultrasound for Neuraxial Block
Analgesia
Primary: Time to Success of Neuraxial Block Placement — 122; 111; 50; 78.5 seconds
Phase 3 N=20 Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
Cirrhosis · Congenital Heart Disease
Primary: Liver Stiffness as Measured by Magnetic Resonance Elastography (MRE) — 5.69; 5.72; 5.02; 5.68 kPa
N/A N=40 Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study
Scleroderma · Systemic Sclerosis
Primary: Eligibility: Number of Patients in the SPIN Cohort Who Meet the Cut-off Thresholds for Eligibility — 24; 16 Participants
N/A N=61 Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
Congestive Heart Failure
Primary: Maximum Plasma Concentration (Cmax) of OPC-41061 on Day 1 — 41.4; 98.6; 149; 282 ng/mL